Literature DB >> 9563278

Reappraisal of Ikeda's classification of alopecia areata: analysis of 356 cases from Chandigarh, India.

V K Sharma1, S Muralidhar, B Kumar.   

Abstract

Three hundred and fifty six patients (234 males, 122 females) with alopecia areata were classified according to Ikeda's classification. The common type of alopecia areata was most frequently seen in 239 (67.13%) patients, followed by atopic in 60 (16.85%), prehypertensive in 48 (13.4%), and autoimmune/endocrine in 9 (2.52%) patients. Severe alopecia did not occur with a higher frequency in atopic or endocrine/autoimmune alopecia areata than in the common type (p > 0.05). Prehypertensive alopecia areata had the lowest frequency of severe alopecia in the present study. The odds for developing severe alopecia were highest (2.6) when onset was before 16 years of age, followed by female sex (2.12), atopy (0.86), autoimmune/endocrine (0.53), and prehypertensive (0.28) types. Alopecia areata should be broadly classified as childhood (< 16 years) and adult onset with subtypes of atopic, autoimmune/endocrine, and common type under both. The prehypertensive type should be combined with the common type of alopecia areata.

Entities:  

Mesh:

Year:  1998        PMID: 9563278     DOI: 10.1111/j.1346-8138.1998.tb02359.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  2 in total

1.  Clinical characteristics and prognostic factors in early-onset alopecia totalis and alopecia universalis.

Authors:  Hyun Hee Cho; Seong Jin Jo; Seung Hwan Paik; Hye Chan Jeon; Kyu Han Kim; Hee Chul Eun; Oh Sang Kwon
Journal:  J Korean Med Sci       Date:  2012-06-29       Impact factor: 2.153

Review 2.  Defining Severity in Alopecia Areata: Current Perspectives and a Multidimensional Framework.

Authors:  Brett A King; Maryanne M Senna; Manabu Ohyama; Antonella Tosti; Rodney D Sinclair; Susan Ball; Justin M Ko; Marc Glashofer; Rodrigo Pirmez; Jerry Shapiro
Journal:  Dermatol Ther (Heidelb)       Date:  2022-03-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.